May 13 2025, David R Brown
Barentz to strengthen its pharmaceuticals business in Asia Pacific with the acquisition of Fengli in China
Barentz, a leading global specialty ingredients solutions provider, is set to acquire 100% of the Fengli Group, one of the market leading specialty chemicals distributors for pharmaceutical excipients and active ingredients in China.
This envisaged acquisition would mean a transformative step for Barentz in the Asia Pacific region, and fully aligns with our strategic ambition to expand and strengthen our global presence.
Derk Jan Terhorst
Group CEO at Barentz
Established in 1996 and headquartered in Beijing, Fengli Group comprises a team of over 100 experienced professionals across five locations in mainland China. It sources high-quality pharmaceutical excipients and active ingredients from 35 international principals and serves more than 2,000 customers in pharmaceutical production, research and development. Fengli Group's technical facilities include an analytical pharma lab for product formulation and support, as well as excipient research, development and application labs.
This intended strategic move would grant Barentz access to the Chinese pharma market and establish a robust sales network centred around innovative excipients and active pharma ingredients (APIs). The partnership would further enhance the service and commercial capabilities of Barentz in China while enabling Fengli Group to expand its international presence. By aligning product portfolios, both companies are expecting to unlock significant synergies and drive accelerated growth.
Mr. Dexin Ma, President at Fengli, comments: “We are thrilled to be partnering with Barentz soon. A collaboration allows us to offer an enhanced array of solutions for excipients, active ingredients and intermediates, combining our collective resources and expertise, while upholding our shared values.”
Derk Jan Terhorst, Group CEO at Barentz adds: “This envisaged acquisition would mean a transformative step for Barentz in the Asia Pacific region, and fully aligns with our strategic ambition to expand and strengthen our global presence. Fengli Group's strong local reputation and established network provide an excellent foundation for growth.”
Post-completion, Mr. Ma and co-founder Mrs. Jingtao Dou, will continue their roles as President and Chief Marketing Officer, respectively, overseeing daily operations and ensuring a smooth integration between the two companies.
Barentz has been active in China for 18 years now and their pharmaceutical and nutraceutical business operates across seven countries in Asia-Pacific.
About Barentz
Barentz is a leading global life science ingredients distributor. The company sources branded specialty ingredients from leading manufacturers worldwide and its ingredient experts provide value-added technical support which includes pre-mixing, blending, ingredient formulation and ingredient testing from its state-of-the-art, customized formulation centers and application laboratories in EMEA, Americas and Asia-Pacific.
Established in 1953, Barentz has operations in more than 70 countries with a strong presence in Europe and North America, and a rapidly growing network in Latin America and Asia-Pacific. With a turnover of €2.3 billion in 2024, the company employs around 2,809 people worldwide and serves over 27,000 customers.
Source(s): Barentz Press Release
Further Information
Visit: https://www.barentz.com